Table 1 |
||
|
Relevant studies |
||
| Condition |
Studies Used to Estimate Cost (Base case, Min-Max) |
Studies Used to Estimate Attribution (Percent Attributed, Min-Max) |
|
|
||
| Coronary heart disease |
Rosamond et al., 2007 [11] ($156.4B, $117B-$196B) |
Barraj et al. 2008 [12] (0.30%, 0.10%–0.50%) |
| Eye health: Age-related macular degeneration |
Halpern et al., 2006 [14]; Schmier et al., 2006a [18]; Schmier et al., 2006b [19]; Salm et al., 2006 [16], 2006; Rein et al., 2006 [15]; Coleman & Yu, 2008 [39] ($10.1B, $198.8 M-$19.96B) |
Seddon et al., 1994 [35]; Handelman et al., 1999 [34]; Gale et al., 2003 [36]; Chung et al., 2004 [37] (9.5%, 4%–15%) |
| Eye health: Cataract |
Rein et al., 2006 [15]; Schmier et al., 2007a (([21]; Schmier et al., 2007b [20] ($20.1B, $15.1B-$25.1B) |
Handelman et al., 1999 [34]; Chasan-Taber et al., 1999 [32]; Vu et al., 2006 [33] (11%, 1%–21%) |
| Muscle mass: Sarcopenia |
Janssen et al., 2004 [26] ($25.7 M, $16.1 M-$36.3 M) |
Assumption (0.50%, 0.38%–0.63%) |
| Fetal health: Neural tube defects |
Ouyang et al., 2007 [40]; Robbins et al., 2007 [41] ($52.0 M, $39.0 M-$64.9 M) |
Shaw et al., 2004 [29]; Zeisel 2000 [38] (9%, 6.75%–11.25%) |
|
|
||
|
Schmier et al. Cost Effectiveness and Resource Allocation 2009 7:7 doi:10.1186/1478-7547-7-7 |
||
